PCT | Jotup

MAIA Biotechnology Announces Publication of International PCT Patent Application Covering Anticancer Telomere-Targeting Compounds

Retrieved on:

Wednesday, January 24, 2024

Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, IP, WIPO, Cancer, PCT, Patent, Pharmaceutical industry

The international patent application covers potential cancer therapies using dinucleotide compounds that target telomeres in cancer cells, and methods for using the dinucleotide compounds to treat cancers alone or before administration with checkpoint inhibitors (CPIs).

Key Points:

The international patent application covers potential cancer therapies using dinucleotide compounds that target telomeres in cancer cells, and methods for using the dinucleotide compounds to treat cancers alone or before administration with checkpoint inhibitors (CPIs).
The new dinucleotides disclosed in the patent application are telomere-targeting molecules, such as THIO fragments or other THIO analogues.
The PCT system streamlines the process for obtaining patent protection globally.
Under the PCT, applicants can seek patent protection in a large number of countries.

Toratani Co., Ltd. Unveils Groundbreaking "Virtuous Circulation Pillow and Mattress" with Patented Technology for Enhanced Deep Breathing Experience

Retrieved on:

Tuesday, January 9, 2024

Risk, Sleep apnea, PCT, Patent, Parasympathetic nervous system, Pressure, Snoring, Sleep, Pharmaceutical industry

TOKYO, Jan. 9, 2024 /PRNewswire/ -- Toratani Co., Ltd. (Kahoku City, Ishikawa Prefecture, Japan) has announced the launch of their innovative Toratani Virtuous Circulation Mattress and Pillow in December 2023. These groundbreaking sleep solutions, comprising both a mattress and a pillow, leverage the pressure exerted by the body to facilitate a natural slowing and deepening of the breath during sleep. They are designed to reduce the risk of snoring and sleep apnea, stimulate the parasympathetic nervous system, and ultimately enhance sleep quality, allowing individuals to enjoy the health benefits of deep breathing while they sleep. The set has secured five patents in Japan and is currently pending a PCT patent application. Plans for international patent applications are also underway.

Key Points:

These groundbreaking sleep solutions, comprising both a mattress and a pillow, leverage the pressure exerted by the body to facilitate a natural slowing and deepening of the breath during sleep.
They are designed to reduce the risk of snoring and sleep apnea, stimulate the parasympathetic nervous system, and ultimately enhance sleep quality, allowing individuals to enjoy the health benefits of deep breathing while they sleep.
The set has secured five patents in Japan and is currently pending a PCT patent application.
The set of Toratani Virtuous Circulation Mattress and Pillow is designed to reduce the risk of snoring and sleep apnea, stimulate the parasympathetic nervous system, and ultimately enhance sleep quality, allowing individuals to enjoy the health benefits of deep breathing while they sleep.

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

Retrieved on:

Monday, January 8, 2024

MDXX, Conference, Partnership, PPH, PCT, Research, Patent, MDMA, University, Innovation, Patient, Safety, P-1, OTC, United States patent law, Pharmacology, Patent Cooperation Treaty, Pharmaceutical industry

“The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that molecule, we are also looking towards a future with novel molecular assets,” said Nick Kadysh, CEO, PharmAla Biotech.

Key Points:

“The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that molecule, we are also looking towards a future with novel molecular assets,” said Nick Kadysh, CEO, PharmAla Biotech.
“P-1 is one of a number of next-generation assets which we are developing, and which promise to bring together both increased safety, and highly beneficial effects like increased neuroplasticity.”
The Patent Prosecution Highway (PPH) speeds up the examination process for corresponding applications filed in participating intellectual property offices.
Under PPH, participating patent offices have agreed that when an applicant receives a ruling from a first patent office indicating that at least one claim is allowable, the applicant may request fast track examination of corresponding claims.
Proof-of-concept testing for P-1 showed significant efficacy and pro-social effect at dosage levels far lower than MDMA, PharmAla’s primary comparator molecule, as well as excellent safety pharmacology.

Slendacor® Weight Management Complex Granted Patent for Research on Thermogenic Benefits

Retrieved on:

Monday, January 8, 2024

MORRISTOWN, N.J., Jan. 8, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced that Slendacor® Weight Management Complex has added to its intellectual property portfolio with a recently granted patent related to new clinical work that studied mechanisms of action behind its weight loss and body shaping benefits, and which demonstrated thermogenic benefits. The invention cited in the patent relates to Slendacor's ability to increase lean body mass and accelerate the conversion of white adipose tissue to the more metabolically active brown or 'beige' adipose tissue. The Japanese patent was part of a global patent initiative by PLT and innovation partner Laila Nutraceuticals and is the first country patent granted as part of a PCT filing across multiple markets. Slendacor is also marketed as Slimvance® in select markets.

Key Points:

MORRISTOWN, N.J., Jan. 8, 2024 /PRNewswire/ -- PLT Health Solutions, Inc. announced that Slendacor® Weight Management Complex has added to its intellectual property portfolio with a recently granted patent related to new clinical work that studied mechanisms of action behind its weight loss and body shaping benefits, and which demonstrated thermogenic benefits.
The Japanese patent was part of a global patent initiative by PLT and innovation partner Laila Nutraceuticals and is the first country patent granted as part of a PCT filing across multiple markets.
Our customers can be confident of the groundbreaking benefits and efficacy they can offer consumers with Slendacor," he added.
Consistent body weight reductions were observed throughout the 16-week trial – starting with statistically significant weight loss at two weeks.

RICTOR Showcases Full Product Line at CES Leading Innovation in Two-Wheel New Energy Vehicles

Retrieved on:

Monday, January 8, 2024

During this event, RICTOR, an innovator in the field of new energy two-wheel vehicles, will unveil its full product lineup, showcasing its latest technologies and achievements in the field.

Key Points:

During this event, RICTOR, an innovator in the field of new energy two-wheel vehicles, will unveil its full product lineup, showcasing its latest technologies and achievements in the field.
Equipped with a 750W Bafang motor and dual battery configuration, which is not only powerful but also solves range anxiety.
These new vehicles not only exhibit a more stylish and dynamic exterior design but also demonstrate substantial improvements in intelligence and safety performance.
As the leading drafting unit, RICTOR has been involved in establishing national general technical and testing standards for the scooter industry.

Peak Bio, Inc. Awarded Patent with Broad Coverage for Thailanstatin-ADC platform technology (PH-1) a Payload with Novel Immunomodulatory Effects that Target RNA Splicing

Retrieved on:

Thursday, January 4, 2024

Doctor of Pharmacy, Conference, Family, SF3B1, PCT, Spacecraft, Patent, PH-1, MBA, Cancer, OTCQB, Interim, European Patent Convention, Patient, Therapy, ADC, PH1, Pharmaceutical industry

Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No.

Key Points:

Pleasanton, CA, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Peak Bio, Inc. ("Peak Bio" or the "Company") (OTCQB) PK: PKBO), announced that it was awarded US Patent No.
The new patent describes properties of potent heteroaryl-substituted Thailanstatin payloads, proprietary non-cleavable and cleavable linkers, and antibody-drug conjugate (ADC) technology derived from it.
The patent granted by the USPTO covers claims for the Company’s potent Thailanstatin payload platform specific to the spliceosome protein, SF3B1.
This patent application is a divisional patent of the Company’s R&D toxin portfolio on Thailanstatin, termed PH-1, building on the portfolio of previously issued patents (Patent No.

4BY4's Pioneering AI Research Elevates Image Enhancement, Published in Prestigious Journal, Scientific Reports

Retrieved on:

Thursday, January 4, 2024

KQ, Research, PCT, Image, Patent, Scientific Reports, Creativity, Nature Portfolio, CCTV, Network, Science, Television

The paper, authored by the firm's in-house AI research powerhouse, Pixell Lab, delves into an advanced AI model for image enhancement, setting a new standard in the realm of visual technology.

Key Points:

The paper, authored by the firm's in-house AI research powerhouse, Pixell Lab, delves into an advanced AI model for image enhancement, setting a new standard in the realm of visual technology.
Published in Scientific Reports, a peer-reviewed journal by Nature Portfolio, the paper exemplifies the rigor and excellence of the research, aligning with the highest standards of scientific inquiry.
Pixell Lab's latest research tackles the complexities of images taken in environments with extreme lighting conditions, presenting a paradigm-shifting method to improve image quality.
The inclusion of our paper in Scientific Reports further validates the creativity and ingenuity of our image preprocessing methods."

Positive opinion from ISA-Israel patent office Provides the ability to file a patent application under the Patent Prosecution Highway (PPH) in the US

Retrieved on:

Monday, December 18, 2023

Invention, Partner, PPH, PCT, Patent, BYND, BCAN, IP, European Patent Convention, EPO, 3D printing

A national phase application corresponding to inventive concept III of PCT/IL2022/050783 was filed on December 7, 2023, as a U.S. utility patent application under the Patent Prosecution Highway (PPH) and has been allocated the application number 18/567,766.

Key Points:

A national phase application corresponding to inventive concept III of PCT/IL2022/050783 was filed on December 7, 2023, as a U.S. utility patent application under the Patent Prosecution Highway (PPH) and has been allocated the application number 18/567,766.
The Company also announced filing in 11 additional jurisdictions, including the European Patent Office (EPO), which includes 38 European countries.
The Company has strategically pursued accelerated processing through the Patent Prosecution Highway (PPH) for one of its inventions, aligning with international efforts to promote work-sharing among patent offices.
The Company is actively collaborating with legal experts, including Reinhold Cohn and Partners, to navigate the complex landscape of patent prosecution and ensure optimal outcomes.

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of PureCycle Technologies, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of November 28, 2023 – (NASDAQ: PCT)

Retrieved on:

Tuesday, November 28, 2023

NEXT, Fraud, Risk, PCT, Security (finance)

DEADLINE: November 28, 2023 Shareholders should not delay in registering for this class action.

Key Points:

DEADLINE: November 28, 2023 Shareholders should not delay in registering for this class action.
The deadline to seek to be a lead plaintiff is November 28, 2023.
The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices.
The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on:

Monday, November 27, 2023

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points:

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
“We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.